Product Description
Calcium folinate is a tetrahydrofolic acid. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Calcium-folinate)
Mechanisms of Action: TS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Denmark | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Japan | Korea | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | New Zealand | Norway | Pakistan | Philippines | Portugal | Russia | Saudi Arabia | Serbia | South Africa | Spain | Sri Lanka | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: ImmunityBio
Company Location: SAN DIEGO CA 92121
Company CEO: Richard Adcock
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Brazil, Canada, Czech Republic, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Portugal, Russia, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 16
Highest Development Phases
Phase 3: Adenocarcinoma|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Pancreatic Cancer
Phase 2: Bile Duct Cancer|Biliary Tract Cancer|Ductal Carcinoma|Hepatocellular Carcinoma|Islet Cell Carcinoma|Neuroendocrine Carcinoma|Pancreatic Ductal Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AndroMETa-GEA | P2 |
Recruiting |
Esophageal Cancer|Gastrointestinal Cancer|Adenocarcinoma |
2030-10-01 |
|
| M24-311 | P2 |
Recruiting |
Colorectal Cancer |
2026-10-01 |
|
| M24-311 | P2 |
Unknown Status |
Colorectal Cancer |
2026-10-01 |
|
| RAMIRIS | P3 |
Unknown Status |
Gastrointestinal Cancer|Esophageal Cancer|Adenocarcinoma |
2025-10-31 |